Antitumor Activity and Pharmacokinetics of TAS‐106, l‐(3‐C‐Ethynyl‐β‐D‐ribo‐pentofuranosyl)cytosine

We examined the effects of dosage schedule on antitumor activity in vitro and in vivo to determine the optimal administration schedule for a new nucleoside antimetabolite l‐(3‐C‐ethynyl‐β‐D‐ribo‐pentofuranosyl)cytosine (ECyd, TAS‐106). The cytotoxicity of TAS‐106 in vitro against human tumors was ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimamoto, Yuji, Fujioka, Akio, Kazuno, Hiromi, Murakami, Yuko, Ohshimo, Hideyuki, Kato, Toshiyuki, Matsuda, Akira, Sasaki, Takuma, Fukushima, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2001
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926715/
https://www.ncbi.nlm.nih.gov/pubmed/11267946
http://dx.doi.org/10.1111/j.1349-7006.2001.tb01101.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926715/
https://www.ncbi.nlm.nih.gov/pubmed/11267946
http://dx.doi.org/10.1111/j.1349-7006.2001.tb01101.x

Ejemplares similares